Abstract
It has been suggested that growth hormone (GH) may play a regulatory role in male reproductive function. To express full anabolic effect in immature boys testosterone apparently requires the presence of GH. In GH-deficient adults, GH replacement therapy exerts a variety of anabolic actions, some of which are similar to the effects of gonadal steroids. However, little is known about the potential effects of GH on gonadal steroids and on dynamic tests of pituitary-gonadal function in adults with GH deficiency. We evaluated the pituitary-gonadal axis in a 4-month double-blind, placebo-controlled GH study in 13 young males with childhood-onset GH deficiency of which 6 had isolated GH deficiency. GH treatment significantly increased serum levels of total IGF-I from 98 (68) to 323 (126) µg/l, free IGF-I from 0.48 (0.47) to 2.24 (1.66) µg/l, IGFBP-3 from 1,874 (1,178) to 3,520 (778) µg/l and ALS levels from 9,182 (5,524) to 16,872 (6,278) µg/l (all p < 0.0001). We found no differences in basal testosterone levels in the 13 patients between the GH and placebo treatment periods (21.9 (5.1) vs. 24.5 (8.1) nmol/l, nonsignificant). Furthermore, no effect of GH on the testicular response to hCG after 72 h was seen compared to placebo (36.2 (6.4) vs. 38.8 (10.3) nmol/l). In addition, no differences existed in basal SHBG, DHT, free testosterone, Δ4-adion and DHEA-S levels. There were no statistically significant differences in maximal FSH and LH response to a GnRH challenge between the GH and the placebo periods (15.7 (5.3) vs. 18.0 (8.8) U/l and 47.0 (26.4) vs. 40.4 (26.5) U/l, respectively). Furthermore, there was no effect on cortisol responses after ACTH between the GH and the placebo periods. However, significantly higher estradiol levels were seen after GH treatment (110 (50) pmol/l) compared to after placebo (89 (34) pmol/l, p = 0.03). Prostate-specific antigen levels decreased after GH treatment compared to after placebo (0.42 (0.54) vs. 0.47 (0.48) µg/l) and this difference almost reached statistical significance (p = 0.059). Inhibin-B levels were significantly lower in hypogonadal patients substituted with androgens, but GH had no effect on inhibin-B levels. In conclusion, GH replacement therapy in 13 GH-deficient young adult males resulted in significant increases in total and free IGF-I as well as in ALS levels in all patients, but had no significant effect on: (1) the pituitary FSH and LH response to GnRH; (2) basal and hCG-stimulated levels of androgens and SHBG; (3) basal inhibin-B levels; (4) ACTH-stimulated cortisol secretion. By contrast, GH administration had subtle anti-androgenic effects in terms of elevated elevated estradiol levels and decreased prostate-specific antigen levels, although both parameters remained within the normal range. Thus, at the level of blood chemistry the effects of GH administration do not appear to involve major alterations in the pituitary-gonadal axis.
References
1.
Balducci R, Toscano V, Mangiantini A, Bianchi P, Guglielmi R, Boscherini B: The effect of growth hormone administration on testicular response during gonadotropin therapy in subjects with combined gonadotropin and growth hormone deficiencies. Acta Endocrinol 1993;128:19–23.
2.
Kulin HE, Samojlik E, Santen R, Santner S: The effect of growth hormone in the Leydig cell response to chorionic gonadotrophin in boys with hypopituitarism. Clin Endocrinol 1981;15:463–472.
3.
Laron Z, Mimouni F, Pertzelan A: Effect of human growth hormone therapy on penile and testicular size in boys with isolated growth hormone deficiency: First year of treatment. Isr J Med Sci 1983;19:338–344.
4.
Laron Z, Sarel R: Penis and testicular size in patients with growth hormone insufficiency. Acta Endocrinol 1970;63:625–633.
5.
Savage MO, Blum WF, Ranke MB, et al: Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome). J Clin Endocrinol Metab 1993;77:1465–1471.
6.
Darendeliler F, Hindmarsh PC, Preece MA, Cox L, Brook CGD: Growth hormone increases rate of pubertal maturation. Acta Endocrinol 1990;122:414–416.
7.
Stanhope R, Albanese A, Hindmarsh P, Brook CGD: The effects of growth hormone therapy on spontaneous sexual development. Horm Res 1992;38(suppl 1):9–13.
8.
Zachmann M, Prader A: Anabolic and androgenic effect of testosterone in sexually immature boys and its dependency on growth hormone. J Clin Endocrinol 1970;40:85–95.
9.
Aynsley-Green A, Zachmann M, Prader A: Interrelation of the therapeutic effects of growth hormone and testosterone on growth in hypopituitarism. J Pediatr 1976;89:992–999.
10.
Pedersen SA, Jørgensen JO, Christiansen JS, Jensen S, Jelnæ JE, Skakkebæk NE: Growth hormone and reproduction: Reduced semen quality in men previously treated for growth hormone deficiency; in Frisch H, Thorner MO (eds): Hormonal Regulation of Growth. New York, Raven Press, 1989, pp 273–282.
11.
Okada Y, Kondo T, Okamoto S, Ogawa M: Induction of ovulation and spermatogenesis by hMG/hCG in hypogonadotropic GH-deficient patients. Endocrinol Jpn 1992;39:31–43.
12.
Gregory JW, Greene SA, Thompson J, Rennie MJ: Effects of oral testosterone undecanoate on growth, body composition, strength, and energy expenditure of adolescent boys. Clin Endocrinol 1992;37:207–213.
13.
Bhansin S, Storer TW, Berman N, et al: Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997;82:407–413.
14.
Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM: Estrogen replacement therapy I: A ten-year prospective study on the relationship to osteoporosis. Obstet Gynecol 1979;53:277–281.
15.
Jørgensen JOL, Pedersen SA, Thuesen L, et al: Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989;i:1221–1225.
16.
Juul A, Pedersen SA, Sørensen S, et al: Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in adults with GH-deficiency of childhood onset. Eur J Endocrinol 1994;131:41–49.
17.
Juul A, Bang P, Hertel NT, et al: Serum insulin-like growth factor-1 in 1030 healthy children, adolescents and adults; relation to age, sex, stage of puberty, testicular size and body mass index. J Clin Endocrinol Metab 1994;78:744–752.
18.
Juul A, Holm K, Kastrup KW, et al: Free insulin-like growth factor (IGF)-I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone-deficiency. J Clin Endocrinol Metab 1997;82:2497–2502.
19.
Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR: A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: Its use for diagnosis of GH deficiency. J Clin Endocrinol Metab 1990;70:1292–1298.
20.
Groome NP, Illingworth PJ, O’Brien M, et al: Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996;81:1401–1405.
21.
Parker CRJ, Ellegood JO, Mahesh VB: Methods for multiple steroid radioimmunoassay. J Steroid Biochem 1975;6:1–8.
22.
Bartsch W: Interrelationships between sex-hormone-binding globulin and testosterone, 5-a-dihydrotestosterone and oestradiol-17 beta in blood of normal men. Maturitas 1980;2:109–118.
23.
Juul A, Müller J, Skakkebæk NE: Prostate specific antigen in boys with precocious puberty before and during gonadal suppression by GnRH agonist treatment. Eur J Endocrinol 1997;136:401–405.
24.
World Health Organization: Laboratory Manual for the Examination of Human Semen and Semen-Cervical Mucus Interaction. Geneva, World Health Organization, 1980.
25.
Giustina A, Scalvini T, Tassi C, et al: Maturation of the regulation of growth hormone secretion in young males with hypogonadotropic hypogonadism pharmacologically exposed to progressive increments in serum testosterone. J Clin Endocrinol Metab 1997;82:1210–1219.
26.
Metzger DL, Kerrigan JR: Androgen receptor blockade with flutamide enhances growth hormone secretion in late pubertal males: Evidence for independent actions of estrogen and androgen. J Clin Endocrinol Metab 1993;76:1147–1152.
27.
Metzger DL, Kerrigan JR: Estrogen blockade with tamoxifen diminishes growth hormone secretion in boys: Evidence for a stimulatory role of endogenous estrogens during male adolescence. J Clin Endocrinol Metab 1994;79:513–518.
28.
Illingworth PJ, Groome NP, Byrd W, et al: Inhibin-B: A likely candidate for the physiologically important form of Inhibin in men. J Clin Endocrinol Metab 1996;81:1321–1325.
29.
Anawalt BD, Bebb RA, Matsumoto AM, et al: Serum inhibin levels reflect sertoli cell function in normal men and men with testicular dysfunction. J Clin Endocrinol Metab 1996;81:3341–3345.
30.
McLachlan RI, Finkel DM, Bremner WJ, Snyder PJ: Serum inhibin concentrations before and during gonadotropin treatment in men with hypogonadotropic hypogonadism: Physiological and clinical implications. J Clin Endocrinol Metab 1990;70:1414–1419.
31.
Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJP, Hill DJ: Differential cellular synthesis of Insulin-like Growth Factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. J Clin Endocrinol Metab 1994;79:1871–1876.
32.
Skjærbæk C, Frystyk J, Møller J, Christiansen JS, Ørskov H: Free and total insulin-like growth factor and insulin-like growth factor binding proteins during 14 days of growth hormone administration in healthy adults. Eur J Endocrinol 1996;135:672–677.
33.
De Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen E: Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J Clin Endocrinol Metab 1996;81:1371–1377.
34.
Thorén M, Hilding A, Baxter RC, Degerblad M, Wivall-Helleryd I-L, Hall K: Serum insulin-like growth factor I (IGF-I), IGF-binding proteins-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1997;82:223–228.
35.
Moustari M, Terraza A, Lobaccaro JM, Sultan C: Action of IGF-I on 5 alpha- reductase activity in genital skin fibroblasts (abstract 40). Horm Res 1992;37:11.
36.
Skakkebæk NE, Bancroft J, Davidson DW, Warner P: Androgen replacement with oral testosterone undecanoate in hypogonadal men: A double blind controlled study. Clin Endocrinol 1981;14:49–61.
37.
Belgorosky A, Martinez A, Domene H, Heinrich JJ, Bergada C, Rivarola MA: High serum sex hormone-binding globulin (SHBG) and low serum non-SHBG-bound testosterone in boys with idiopathic hypopituitarism: Effect of recombinant human growth hormone treatment. J Clin Endocrinol Metab 1987;65:1107–111.
38.
Gafny M, Silbergeld A, Klinger B, Wasserman M, Laron Z: Comparative effects of GH, IGF-I and insulin on sex hormone binding globulin. Clin Endocrinol 1994;41:169–175.
39.
Anapliotou MGL, Evagellou E, Kastanias I, Liparaki M, Psara P, Goulandris N: Effect of growth hormone cotreatment with human chorionic gonadotropin in testicular steroidogenesis and seminal insulin-like growth factor-1 in oligozoospermia. Fertil Steril 1996;66:305–311.
40.
Sauder SE, Corley KP, Hopwood NJ, Kelch RP: Subnormal gonadotropin resonse to gonadotropin releasing hormone persist into puberty in children with isolated growth hormone deficiency. J Clin Endocrinol Metab 1981;53:1186–1192.
41.
Kelch RP, Markovs M, Huss J: LH and FSH responsiveness to intravenous gonadotropin-releasing hormone (GnRH) in children with hypothalamic or pituitary disorders: Lacks of effect of replacement therapy with human growth hormone. J Clin Endocrinol Metab 1976;42:1104–1113.
42.
Sklar CA, Ulmstrom RA: Effect of human growth hormone on adrenal androgens in children with growth hormone deficiency. Horm Res 1984;20:166–171.
43.
Castro-Magana M, Maddaiah VT, Collipp PJ, Angulo M: Synergistic effects of growth hormone therapy on plasma levels of 11-deoxycortisol and cortisol in growth hormone-deficient children. J Clin Endocrinol Metab 1983;56:662–667.
44.
Weinstein R, Kelch R, Jenner M: Secretion of androgens and estrogens by the normal and abnormal human testis. J Clin Invest 1974;53:1–7.
45.
Keenan BS, Richards GE, Ponder SW, Dallas JS, Nagamani M, Smith ER: Androgen-stimulated pubertal growth: The effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-I in the treatment of short stature and delayed puberty. J Clin Endocrinol Metab 1993;76:996–1001.
46.
Stamey TA, Kabalin JN, Ferrari M, Yang N: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 1989;141:1088–1090.
47.
Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate SR: Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996;81:3774–3782.
48.
Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR: Insulin-like growth factor-binding proteins (IGFBP)-4, -5 and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization. J Clin Endocrinol Metab 1996;81:3783–3792.
49.
Cohen P, Graves HCB, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046–1053.
50.
Cohn L, Feller AG, Draper MW, Rudman IW, Rudman D: Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin Endocrinol 1993;39:417–425.
51.
Blok GJ, De Boer H, Gooren LJG, Van der Veen EA: Growth hormone substitution in adults growth hormone-deficient men augment androgen effects on the skin. Clin Endocrinol 1997;47:36.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
